← Back to patent-cliff list
TR-115
Tier C — Watch / tradeTR-115
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EZH2
Indications (approved)：结外NK-T细胞淋巴瘤, Peripheral T-cell lymphoma, 成熟T细胞和NK细胞淋巴瘤, Bladder cancer, Ovarian cancer, Gastric cancer, Endometrial cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase III
2026-05-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TR-115?
Approved indications include: 结外NK-T细胞淋巴瘤, Peripheral T-cell lymphoma, 成熟T细胞和NK细胞淋巴瘤, Bladder cancer, Ovarian cancer, Gastric cancer, Endometrial cancer, Solid tumour.
When does the TR-115 patent expire?
No public expiry year is available for TR-115 yet; this page updates once verified.
How do I get a quote for TR-115 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29